We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
AMPE Ampio Pharmaceuticals
An SI Board Since May 2014
Posts SubjectMarks Bans Symbol
28 2 0 AMPE
Emcee:  Savant Type:  Moderated
AMPIO PHARMACEUTICALS..a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
28Happy Friday [graphic]Chartgod-January 31
27 (up 30%) Ampio Pharmaceuticals Announces Positive Study Results on OSavant-5/21/2015
26 AMPIO Announces Ampion(TM) STRIDE Study ResultsENGLEWOOD, ColSavant-4/20/2015
25Whadda ya know, turned into a 50% move to the'm wondering ifSavant-3/19/2015
24AMPE X-over alert... pps ...100 dsma closing in on x-ing above 200 dsma... I seSavant-3/5/2015
23 Ampio Pharma announces results of the double-blind, multiple injectiSavant-2/25/2015
22Ampio Pharma unit Luoxis establishes initial European distribution network for RSavant-1/23/2015
21 Luoxis to Present at Biotech Showcase 2015ENGLEWOOD, Colo., JSavant-1/9/2015
20 Vyrix Pharmaceuticals to Present at Biotech Showcase(TM) 2015ENGLEWOSavant-1/9/2015
19 Ampio Announces Results of the Open Label Portion of the Multiple Savant-12/4/2014
18 AMPE subsidiary -Luoxis Announces Presentation of Multiple Studies VSavant-11/24/2014
17 Ampio updates status of clinical trials and manufacturing facilityENSavant-11/12/2014
16Strut & Stride.... Ampio Announces Results of the Open Label PorSavant-10/16/2014
15 AMPE...Letter to the Ampio Shareholders in Regard to the STEP Study and Ampio&#Savant-8/25/2014
14Added to put sales..should have waited a day or so...impatience, sometimes it heSavant-8/22/2014
13 Ampio Pharma Cut to Hold From Buy by JefferiesSavant-8/22/2014
12A few mumbling thoughts....So, if the product loses potency if frozen, and the sSavant-8/21/2014
11 Ampio reports that due to temperature deviations below product Savant-8/21/2014
10 Analysis Of Available Data From Optimeyes Study (Blinded And Open LaSavant-8/21/2014
9 Luoxis Announces Presentation of Positive Clinical Findings from FivSavant-8/21/2014
8 Ampio Announces Very Positive Results of the Open Label Portion of tSavant-8/21/2014
7 Luoxis Broadens Global Research Network for RedoxSYS(TM) Savant-8/21/2014
6 Ampio announces positive results on the open label portion of the MuSavant-8/21/2014
5 Ampio Pharmaceuticals announces the FDA has issued a written responsSavant-8/21/2014
4ENGLEWOOD, Colo., July 23 2014 /PRNewswire/ -- Ampio Pharmaceuticals, IncSavant-8/21/2014
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):